{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T05:26:19Z","timestamp":1794461179472,"version":"4.9.1"},"reference-count":127,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T00:00:00Z","timestamp":1736553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T00:00:00Z","timestamp":1736553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01DE027809"],"award-info":[{"award-number":["R01DE027809"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01DE027809"],"award-info":[{"award-number":["R01DE027809"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01DE027809"],"award-info":[{"award-number":["R01DE027809"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01DE027809"],"award-info":[{"award-number":["R01DE027809"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01DE027809"],"award-info":[{"award-number":["R01DE027809"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01DE027809"],"award-info":[{"award-number":["R01DE027809"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01DE027809"],"award-info":[{"award-number":["R01DE027809"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Adenoid cystic carcinoma (ACC) is a rare glandular malignancy, commonly originating in salivary glands of the head and neck. Given its protracted growth, ACC is usually diagnosed in advanced stage. Treatment of ACC is limited to surgery and\/or adjuvant radiotherapy, which often fails to prevent disease recurrence, and no FDA-approved targeted therapies are currently available. As such, identification of new therapeutic targets specific to ACC is crucial for improved patients\u2019 outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>After thoroughly evaluating the gene expression and signaling patterns characterizing ACC, we applied PandaOmics (an AI-driven software platform for novel therapeutic target discovery) on the unique transcriptomic dataset of 87 primary ACCs. Identifying protein arginine methyl transferase 5 (PRMT5) as a putative candidate with the top-scored druggability, we next determined the applicability of PRMT5 inhibitors (PRT543 and PRT811) using ACC cell lines, organoids, and patient derived xenograft (PDX) models. Molecular changes associated with response to PRMT5 inhibition and anti-proliferative effect of the combination therapy with lenvatinib was then analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Using a comprehensive AI-powered engine for target identification, PRMT5 was predicted among potential therapeutic target candidates for ACC. Here we show that monotherapy with selective PRMT5 inhibitors induced a potent anti-tumor activity across several cellular and animal models of ACC, which was paralleled by downregulation of genes associated with ACC tumorigenesis, including\n                      <jats:italic>MYB<\/jats:italic>\n                      and\n                      <jats:italic>MYC<\/jats:italic>\n                      (the recognized drivers of ACC progression). Furthermore, as a subset of genes targeted by lenvatinib is upregulated in ACC, we demonstrate that addition of lenvatinib enhanced the growth inhibitory effect of PRMT5 blockade in vitro, suggesting a potential clinical benefit for patients expressing lenvatinib favorable molecular profile.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Taken together, our study underscores the role of PRMT5 in ACC oncogenesis and provides a strong rationale for the clinical development of PRMT5 inhibitors as a targeted monotherapy or combination therapy for treatment of patients with this rare disease, based on the analysis of their underlying molecular profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-024-03270-x","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T21:58:58Z","timestamp":1736546338000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["PRMT5 inhibition has a potent anti-tumor activity against adenoid cystic carcinoma of salivary glands"],"prefix":"10.1186","volume":"44","author":[{"given":"Vasudha","family":"Mishra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alka","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Korzinkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangying","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Wing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoria","family":"Sarkisova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin L.","family":"Koppayi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Pogorelskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oksana","family":"Glushchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manu","family":"Sundaresan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkat","family":"Thodima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"Scherle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Trzcinska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Ozerov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Everett E.","family":"Vokes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grayson","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank W.","family":"Pun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander T.","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark W.","family":"Lingen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Ruggeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari J.","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Zhavoronkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishant","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgeny","family":"Izumchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,11]]},"reference":[{"key":"3270_CR1","doi-asserted-by":"publisher","first-page":"e13600","DOI":"10.1200\/JCO.2020.38.15_suppl.e13600","volume":"38","author":"TAC Boyle","year":"2020","unstructured":"Boyle TAC, Laurent SS, Semus S, Joseph N. Epidemiology of adenoid cystic carcinoma in the United States. J Clin Oncol. 2020;38:e13600\u201313600.","journal-title":"J Clin Oncol"},{"key":"3270_CR2","doi-asserted-by":"publisher","first-page":"4444","DOI":"10.1002\/cncr.27408","volume":"118","author":"CL Ellington","year":"2012","unstructured":"Ellington CL, et al. Adenoid cystic carcinoma of the head and neck: incidence and survival trends based on 1973\u20132007 Surveillance, Epidemiology, and end results data. Cancer. 2012;118:4444\u201351.","journal-title":"Cancer"},{"key":"3270_CR3","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.oooo.2012.04.008","volume":"114","author":"FP Fonseca","year":"2012","unstructured":"Fonseca FP, et al. Clinicopathologic analysis of 493 cases of salivary gland tumors in a Southern Brazilian population. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;114:230\u20139.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"3270_CR4","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.oraloncology.2015.10.002","volume":"51","author":"K Bj\u00f8rndal","year":"2015","unstructured":"Bj\u00f8rndal K, et al. Salivary adenoid cystic carcinoma in Denmark 1990\u20132005: outcome and independent prognostic factors including the benefit of radiotherapy. Results of the Danish Head and Neck Cancer Group (DAHANCA). Oral Oncol. 2015;51:1138\u201342.","journal-title":"Oral Oncol"},{"key":"3270_CR5","doi-asserted-by":"publisher","first-page":"3354","DOI":"10.1002\/cncr.32208","volume":"125","author":"AJ Hay","year":"2019","unstructured":"Hay AJ, et al. Minor salivary gland tumors of the head and neck-memorial Sloan Kettering experience: incidence and outcomes by site and histological type. Cancer. 2019;125:3354\u201366.","journal-title":"Cancer"},{"key":"3270_CR6","unstructured":"Pfister DG, et al. Version 2.2020, NCCN Clinical Practice guidelines in Oncology. J Natl Compr Canc Netw. 2020;18:873\u201398. Head and Neck Cancers."},{"key":"3270_CR7","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/hed.10126","volume":"24","author":"JE van der Wal","year":"2002","unstructured":"van der Wal JE, Becking AG, Snow GB, van der Waal I. Distant metastases of adenoid cystic carcinoma of the salivary glands and the value of diagnostic examinations during follow-up. Head Neck. 2002;24:779\u201383.","journal-title":"Head Neck"},{"key":"3270_CR8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11864-022-01043-2","volume":"24","author":"AJ Kacew","year":"2023","unstructured":"Kacew AJ, Hanna GJ. Systemic and targeted therapies in Adenoid cystic carcinoma. Curr Treat Options Oncol. 2023;24:45\u201360.","journal-title":"Curr Treat Options Oncol"},{"key":"3270_CR9","doi-asserted-by":"publisher","first-page":"103886","DOI":"10.1016\/j.critrevonc.2022.103886","volume":"181","author":"VP Wagner","year":"2023","unstructured":"Wagner VP, et al. Drug-based therapy for advanced adenoid cystic carcinoma: current landscape and challenges based on an overview of registered clinical trials. Crit Rev Oncol Hematol. 2023;181:103886.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3270_CR10","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s11912-022-01233-z","volume":"24","author":"LG de Sousa","year":"2022","unstructured":"de Sousa LG, Neto FL, Lin J, Ferrarotto R. Treatment of recurrent or metastatic adenoid cystic carcinoma. Curr Oncol Rep. 2022;24:621\u201331.","journal-title":"Curr Oncol Rep"},{"key":"3270_CR11","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/ng.2643","volume":"45","author":"AS Ho","year":"2013","unstructured":"Ho AS, et al. The mutational landscape of adenoid cystic carcinoma. Nat Genet. 2013;45:791\u20138.","journal-title":"Nat Genet"},{"key":"3270_CR12","doi-asserted-by":"publisher","first-page":"18740","DOI":"10.1073\/pnas.0909114106","volume":"106","author":"M Persson","year":"2009","unstructured":"Persson M, et al. Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci U S A. 2009;106:18740\u20134.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3270_CR13","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s11864-022-01001-y","volume":"23","author":"LG de Sousa","year":"2022","unstructured":"de Sousa LG, Jovanovic K, Ferrarotto R. Metastatic adenoid cystic carcinoma: genomic Landscape and emerging treatments. Curr Treat Options Oncol. 2022;23:1135\u201350.","journal-title":"Curr Treat Options Oncol"},{"key":"3270_CR14","doi-asserted-by":"publisher","first-page":"66239","DOI":"10.18632\/oncotarget.11288","volume":"7","author":"PT Wysocki","year":"2016","unstructured":"Wysocki PT, et al. Adenoid cystic carcinoma: emerging role of translocations and gene fusions. Oncotarget. 2016;7:66239\u201354.","journal-title":"Oncotarget"},{"key":"3270_CR15","doi-asserted-by":"publisher","first-page":"4722","DOI":"10.1158\/1078-0432.CCR-10-0463","volume":"16","author":"Y Mitani","year":"2010","unstructured":"Mitani Y, et al. Comprehensive analysis of the MYB-NFIB gene fusion in salivary adenoid cystic carcinoma: incidence, variability, and clinicopathologic significance. Clin Cancer Res. 2010;16:4722\u201331.","journal-title":"Clin Cancer Res"},{"key":"3270_CR16","doi-asserted-by":"publisher","first-page":"4276","DOI":"10.1172\/JCI128227","volume":"129","author":"AS Ho","year":"2019","unstructured":"Ho AS, et al. Genetic hallmarks of recurrent\/metastatic adenoid cystic carcinoma. J Clin Invest. 2019;129:4276\u201389.","journal-title":"J Clin Invest"},{"key":"3270_CR17","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1200\/JCO.2016.67.5264","volume":"35","author":"R Ferrarotto","year":"2017","unstructured":"Ferrarotto R, et al. Activating NOTCH1 mutations define a distinct subgroup of patients with adenoid cystic Carcinoma who have poor prognosis, propensity to bone and liver metastasis, and potential responsiveness to Notch1 inhibitors. J Clin Oncol. 2017;35:352\u201360.","journal-title":"J Clin Oncol"},{"key":"3270_CR18","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/s41419-022-05133-9","volume":"13","author":"R Ferrarotto","year":"2022","unstructured":"Ferrarotto R, et al. AL101, a gamma-secretase inhibitor, has potent antitumor activity against adenoid cystic carcinoma with activated NOTCH signaling. Cell Death Dis. 2022;13:678.","journal-title":"Cell Death Dis"},{"key":"3270_CR19","doi-asserted-by":"publisher","first-page":"6046","DOI":"10.1200\/JCO.2022.40.16_suppl.6046","volume":"40","author":"R Ferrarotto","year":"2022","unstructured":"Ferrarotto R, et al. Results of ACCURACY: a phase 2 trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent\/metastatic (R\/M) adenoid cystic carcinoma (ACC) harboring notch activating mutations (Notchmut). J Clin Oncol. 2022;40:6046\u20136046.","journal-title":"J Clin Oncol"},{"key":"3270_CR20","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.1200\/JCO.2021.39.15_suppl.3020","volume":"39","author":"EL Miranda","year":"2021","unstructured":"Miranda EL, et al. Phase 1 study of CB-103, a novel first-in-class inhibitor of the CSL-NICD gene transcription factor complex in human cancers. J Clin Oncol. 2021;39:3020\u20133020.","journal-title":"J Clin Oncol"},{"key":"3270_CR21","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1158\/1078-0432.CCR-20-1192","volume":"27","author":"R Ferrarotto","year":"2021","unstructured":"Ferrarotto R, et al. Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas defines molecular subtypes and identifies therapeutic targets. Clin Cancer Res. 2021;27:852\u201364.","journal-title":"Clin Cancer Res"},{"key":"3270_CR22","doi-asserted-by":"publisher","first-page":"677051","DOI":"10.3389\/fonc.2021.677051","volume":"11","author":"EC Broner","year":"2021","unstructured":"Broner EC, et al. Doublecortin-like kinase 1 (DCLK1) is a Novel NOTCH Pathway Signaling Regulator in Head and Neck squamous cell carcinoma. Front Oncol. 2021;11:677051.","journal-title":"Front Oncol"},{"key":"3270_CR23","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1080\/15384101.2017.1327492","volume":"16","author":"GN Stamatas","year":"2017","unstructured":"Stamatas GN, et al. An analysis of gene expression data involving examination of signaling pathways activation reveals new insights into the mechanism of action of minoxidil topical foam in men with androgenetic alopecia. Cell Cycle. 2017;16:1578\u201384.","journal-title":"Cell Cycle"},{"key":"3270_CR24","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1096\/fj.201600675r","volume":"31","author":"S Pasteuning-Vuhman","year":"2017","unstructured":"Pasteuning-Vuhman S, et al. New function of the myostatin\/activin type I receptor (ALK4) as a mediator of muscle atrophy and muscle regeneration. FASEB J. 2017;31:238\u201355.","journal-title":"FASEB J"},{"key":"3270_CR25","doi-asserted-by":"publisher","first-page":"914017","DOI":"10.3389\/fnagi.2022.914017","volume":"14","author":"FW Pun","year":"2022","unstructured":"Pun FW, et al. Identification of therapeutic targets for amyotrophic lateral sclerosis using PandaOmics - An AI-Enabled Biological Target Discovery platform. Front Aging Neurosci. 2022;14:914017.","journal-title":"Front Aging Neurosci"},{"key":"3270_CR26","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.18632\/aging.203960","volume":"14","author":"FW Pun","year":"2022","unstructured":"Pun FW, et al. Hallmarks of aging-based dual-purpose disease and age-associated targets predicted using PandaOmics AI-powered discovery engine. Aging. 2022;14:2475\u2013506.","journal-title":"Aging"},{"key":"3270_CR27","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1038\/s41587-019-0224-x","volume":"37","author":"A Zhavoronkov","year":"2019","unstructured":"Zhavoronkov A, et al. Deep learning enables rapid identification of potent DDR1 kinase inhibitors. Nat Biotechnol. 2019;37:1038\u201340.","journal-title":"Nat Biotechnol"},{"key":"3270_CR28","doi-asserted-by":"publisher","first-page":"112252","DOI":"10.1016\/j.biopha.2021.112252","volume":"144","author":"Y Chen","year":"2021","unstructured":"Chen Y, et al. Targeting protein arginine methyltransferase 5 in cancers: roles, inhibitors and mechanisms. Biomed Pharmacother. 2021;144:112252.","journal-title":"Biomed Pharmacother"},{"key":"3270_CR29","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1399-0004.2011.01809.x","volume":"81","author":"R Kanwal","year":"2012","unstructured":"Kanwal R, Gupta S. Epigenetic modifications in cancer. Clin Genet. 2012;81:303\u201311.","journal-title":"Clin Genet"},{"key":"3270_CR30","doi-asserted-by":"crossref","unstructured":"Cheng Y et al. Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials. Signal Transduct Tar 4(2019).","DOI":"10.1038\/s41392-019-0095-0"},{"key":"3270_CR31","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nrc3409","volume":"13","author":"Y Yang","year":"2013","unstructured":"Yang Y, Bedford MT. Protein arginine methyltransferases and cancer. Nat Rev Cancer. 2013;13:37\u201350.","journal-title":"Nat Rev Cancer"},{"key":"3270_CR32","doi-asserted-by":"crossref","unstructured":"Guccione E, Richard S, Author, Correction. The regulation, functions and clinical relevance of arginine methylation. Nat Rev Mol Cell Biol. 2019;20:567.","DOI":"10.1038\/s41580-019-0166-7"},{"key":"3270_CR33","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.molcel.2016.11.003","volume":"65","author":"RS Blanc","year":"2017","unstructured":"Blanc RS, Richard S. Arginine methylation: the coming of Age. Mol Cell. 2017;65:8\u201324.","journal-title":"Mol Cell"},{"key":"3270_CR34","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/s41417-021-00327-3","volume":"29","author":"E Beketova","year":"2022","unstructured":"Beketova E, Owens JL, Asberry AM, Hu C-D. PRMT5: a putative oncogene and therapeutic target in prostate cancer. Cancer Gene Ther. 2022;29:264\u201376.","journal-title":"Cancer Gene Ther"},{"key":"3270_CR35","doi-asserted-by":"publisher","first-page":"101042831769591","DOI":"10.1177\/1010428317695917","volume":"39","author":"Y Wu","year":"2017","unstructured":"Wu Y, Wang Z, Zhang J, Ling R. Elevated expression of protein arginine methyltransferase 5 predicts the poor prognosis of breast cancer. Tumour Biol. 2017;39:1010428317695917.","journal-title":"Tumour Biol"},{"key":"3270_CR36","doi-asserted-by":"publisher","first-page":"14847","DOI":"10.18632\/oncotarget.14682","volume":"8","author":"B Kumar","year":"2017","unstructured":"Kumar B, et al. Nuclear PRMT5, cyclin D1 and IL-6 are associated with poor outcome in oropharyngeal squamous cell carcinoma patients and is inversely associated with p16-status. Oncotarget. 2017;8:14847\u201359.","journal-title":"Oncotarget"},{"key":"3270_CR37","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.canlet.2018.04.019","volume":"427","author":"PY Jing","year":"2018","unstructured":"Jing PY, et al. Protein arginine methyltransferase 5 promotes lung cancer metastasis via the epigenetic regulation of miR-99 family\/FGFR3 signaling. Cancer Lett. 2018;427:38\u201348.","journal-title":"Cancer Lett"},{"key":"3270_CR38","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3892\/ijo.2017.3833","volume":"50","author":"D Shimizu","year":"2017","unstructured":"Shimizu D, et al. The protein arginine methyltransferase 5 promotes malignant phenotype of hepatocellular carcinoma cells and is associated with adverse patient outcomes after curative hepatectomy. Int J Oncol. 2017;50:381\u20136.","journal-title":"Int J Oncol"},{"key":"3270_CR39","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/pin.12666","volume":"68","author":"Y Amano","year":"2018","unstructured":"Amano Y, et al. Expression of protein arginine methyltransferase-5 in oral squamous cell carcinoma and its significance in epithelial-to-mesenchymal transition. Pathol Int. 2018;68:359\u201366.","journal-title":"Pathol Int"},{"key":"3270_CR40","doi-asserted-by":"publisher","first-page":"58","DOI":"10.36401\/JIPO-22-1","volume":"5","author":"K Feustel","year":"2022","unstructured":"Feustel K, Falchook GS. Protein arginine methyltransferase 5 (PRMT5) inhibitors in Oncology clinical trials: a review. J Immunotherapy Precision Oncol. 2022;5:58\u201367.","journal-title":"J Immunotherapy Precision Oncol"},{"key":"3270_CR41","first-page":"2863","volume":"15","author":"A Olsen","year":"2023","unstructured":"Olsen A, et al. Identification of dual-purpose therapeutic targets implicated in aging and glioblastoma multiforme using PandaOmics - an AI-enabled biological target discovery platform. Aging. 2023;15:2863\u201376.","journal-title":"Aging"},{"key":"3270_CR42","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1039\/D2SC05709C","volume":"14","author":"F Ren","year":"2023","unstructured":"Ren F, et al. AlphaFold accelerates artificial intelligence powered drug discovery: efficient discovery of a novel CDK20 small molecule inhibitor. Chem Sci. 2023;14:1443\u201352.","journal-title":"Chem Sci"},{"key":"3270_CR43","doi-asserted-by":"crossref","unstructured":"Bhagwat N et al., Abstract 2915: Preclinical characterization of PRT543, a potent and selective inhibitor of protein arginine methyltransferase 5 (PRMT5), with broad antitumor activity in in vitro and in vivo models. Cancer Research. 2020;80:2915\u20132915.","DOI":"10.1158\/1538-7445.AM2020-2915"},{"key":"3270_CR44","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12859-020-3442-9","volume":"21","author":"Z Dezs\u0151","year":"2020","unstructured":"Dezs\u0151 Z, Ceccarelli M. Machine learning prediction of oncology drug targets based on protein and network properties. BMC Bioinformatics. 2020;21:104.","journal-title":"BMC Bioinformatics"},{"key":"3270_CR45","doi-asserted-by":"publisher","first-page":"106634","DOI":"10.1016\/j.oraloncology.2023.106634","volume":"149","author":"R Ferrarotto","year":"2023","unstructured":"Ferrarotto R, et al. PRT543, a protein arginine methyltransferase 5 inhibitor, in patients with advanced adenoid cystic carcinoma: an open-label, phase I dose-expansion study. Oral Oncol. 2023;149:106634.","journal-title":"Oral Oncol"},{"key":"3270_CR46","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1200\/JCO.18.01859","volume":"37","author":"V Tchekmedyian","year":"2019","unstructured":"Tchekmedyian V, et al. Phase II study of Lenvatinib in patients with Progressive, recurrent or metastatic adenoid cystic carcinoma. J Clin Oncol. 2019;37:1529\u201337.","journal-title":"J Clin Oncol"},{"key":"3270_CR47","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1002\/cncr.32754","volume":"126","author":"LD Locati","year":"2020","unstructured":"Locati LD, et al. Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: activity and quality of life. Cancer. 2020;126:1888\u201394.","journal-title":"Cancer"},{"key":"3270_CR48","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1097\/PAS.0b013e3180dc928c","volume":"31","author":"RR Seethala","year":"2007","unstructured":"Seethala RR, Hunt JL, Baloch ZW, Livolsi VA. Leon Barnes, E. Adenoid cystic carcinoma with high-grade transformation: a report of 11 cases and a review of the literature. Am J Surg Pathol. 2007;31:1683\u201394.","journal-title":"Am J Surg Pathol"},{"key":"3270_CR49","doi-asserted-by":"publisher","first-page":"10","DOI":"10.14806\/ej.17.1.200","volume":"17","author":"M Martin","year":"2011","unstructured":"Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet J. 2011;17:10\u20132.","journal-title":"EMBnet J"},{"key":"3270_CR50","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12864-017-4414-y","volume":"19","author":"M Callari","year":"2018","unstructured":"Callari M, et al. Computational approach to discriminate human and mouse sequences in patient-derived tumour xenografts. BMC Genomics. 2018;19:19.","journal-title":"BMC Genomics"},{"key":"3270_CR51","doi-asserted-by":"publisher","first-page":"3211","DOI":"10.1093\/bioinformatics\/bts611","volume":"28","author":"E Kopylova","year":"2012","unstructured":"Kopylova E, No\u00e9 L, Touzet H. SortMeRNA: fast and accurate filtering of ribosomal RNAs in metatranscriptomic data. Bioinformatics. 2012;28:3211\u20137.","journal-title":"Bioinformatics"},{"key":"3270_CR52","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15\u201321.","journal-title":"Bioinformatics"},{"key":"3270_CR53","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s13059-019-1842-9","volume":"20","author":"BJ Haas","year":"2019","unstructured":"Haas BJ, et al. Accuracy assessment of fusion transcript detection via read-mapping and de novo fusion transcript assembly-based methods. Genome Biol. 2019;20:213.","journal-title":"Genome Biol"},{"key":"3270_CR54","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1101\/gr.257246.119","volume":"31","author":"S Uhrig","year":"2021","unstructured":"Uhrig S, et al. Accurate and efficient detection of gene fusions from RNA sequencing data. Genome Res. 2021;31:448\u201360.","journal-title":"Genome Res"},{"key":"3270_CR55","doi-asserted-by":"crossref","unstructured":"Suehnholz SP et al. Quantifying the Expanding Landscape of clinical actionability for patients with Cancer. Cancer Discov (2023).","DOI":"10.1158\/2159-8290.CD-23-0467"},{"key":"3270_CR56","unstructured":"Chakravarty D et al. OncoKB: a Precision Oncology Knowledge Base. JCO Precis Oncol 2017(2017)."},{"key":"3270_CR57","doi-asserted-by":"publisher","first-page":"13427","DOI":"10.1038\/ncomms13427","volume":"7","author":"IV Ozerov","year":"2016","unstructured":"Ozerov IV, et al. In silico pathway Activation Network Decomposition Analysis (iPANDA) as a method for biomarker development. Nat Commun. 2016;7:13427.","journal-title":"Nat Commun"},{"key":"3270_CR58","doi-asserted-by":"publisher","first-page":"D687","DOI":"10.1093\/nar\/gkab1028","volume":"50","author":"M Gillespie","year":"2022","unstructured":"Gillespie M, et al. The reactome pathway knowledgebase 2022. Nucleic Acids Res. 2022;50:D687\u201392.","journal-title":"Nucleic Acids Res"},{"key":"3270_CR59","doi-asserted-by":"crossref","unstructured":"Fang Z, Liu X, Peltz G. GSEApy: a comprehensive package for performing gene set enrichment analysis in Python. Bioinformatics 39(2022).","DOI":"10.1093\/bioinformatics\/btac757"},{"key":"3270_CR60","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/1471-2105-14-128","volume":"14","author":"EY Chen","year":"2013","unstructured":"Chen EY, et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics. 2013;14:128.","journal-title":"BMC Bioinformatics"},{"key":"3270_CR61","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1101\/gr.107524.110","volume":"20","author":"A McKenna","year":"2010","unstructured":"McKenna A, et al. The genome analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20:1297\u2013303.","journal-title":"Genome Res"},{"key":"3270_CR62","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/bioinformatics\/btp698","volume":"26","author":"H Li","year":"2010","unstructured":"Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics. 2010;26:589\u201395.","journal-title":"Bioinformatics"},{"key":"3270_CR63","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1093\/nar\/gkq603","volume":"38","author":"K Wang","year":"2010","unstructured":"Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38:e164.","journal-title":"Nucleic Acids Res"},{"key":"3270_CR64","doi-asserted-by":"publisher","first-page":"lqaa078","DOI":"10.1093\/nargab\/lqaa078","volume":"2","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Parmigiani G, Johnson WE. ComBat-seq: batch effect adjustment for RNA-seq count data. NAR Genom Bioinform. 2020;2:lqaa078.","journal-title":"NAR Genom Bioinform"},{"key":"3270_CR65","doi-asserted-by":"publisher","first-page":"1144945","DOI":"10.3389\/fgene.2023.1144945","volume":"14","author":"YF Tang","year":"2023","unstructured":"Tang YF, et al. Transcriptomic insights into adenoid cystic carcinoma via RNA sequencing. Front Genet. 2023;14:1144945.","journal-title":"Front Genet"},{"key":"3270_CR66","first-page":"1085","volume":"13","author":"Z Liu","year":"2021","unstructured":"Liu Z, et al. Potential targets identified in adenoid cystic carcinoma point out new directions for further research. Am J Transl Res. 2021;13:1085\u2013108.","journal-title":"Am J Transl Res"},{"key":"3270_CR67","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1158\/2159-8290.CD-15-0859","volume":"6","author":"KJ Brayer","year":"2016","unstructured":"Brayer KJ, Frerich CA, Kang H, Ness SA. Recurrent fusions in MYB and MYBL1 define a common, transcription factor-driven oncogenic pathway in salivary gland adenoid cystic carcinoma. Cancer Discov. 2016;6:176\u201387.","journal-title":"Cancer Discov"},{"key":"3270_CR68","doi-asserted-by":"publisher","first-page":"4123","DOI":"10.18632\/oncotarget.27797","volume":"11","author":"J Meinrath","year":"2020","unstructured":"Meinrath J, et al. Expression profiling on subclasses of primary parotid gland carcinomas. Oncotarget. 2020;11:4123\u201337.","journal-title":"Oncotarget"},{"key":"3270_CR69","doi-asserted-by":"publisher","first-page":"7341","DOI":"10.18632\/oncotarget.23641","volume":"9","author":"CA Frerich","year":"2018","unstructured":"Frerich CA, et al. Transcriptomes define distinct subgroups of salivary gland adenoid cystic carcinoma with different driver mutations and outcomes. Oncotarget. 2018;9:7341\u201358.","journal-title":"Oncotarget"},{"key":"3270_CR70","doi-asserted-by":"publisher","first-page":"4320","DOI":"10.1158\/1078-0432.CCR-10-2992","volume":"17","author":"C Shao","year":"2011","unstructured":"Shao C, et al. Integrated, genome-wide screening for hypomethylated oncogenes in salivary gland adenoid cystic carcinoma. Clin Cancer Res. 2011;17:4320\u201330.","journal-title":"Clin Cancer Res"},{"key":"3270_CR71","doi-asserted-by":"crossref","unstructured":"He J et al. Lysophosphatidic acid receptor 6 (LPAR6) is a potential Biomarker Associated with Lung Adenocarcinoma. Int J Environ Res Public Health 18(2021).","DOI":"10.3390\/ijerph182111038"},{"key":"3270_CR72","doi-asserted-by":"publisher","first-page":"1191218","DOI":"10.3389\/fonc.2023.1191218","volume":"13","author":"FJ da Silva","year":"2023","unstructured":"da Silva FJ, et al. Salivary glands adenoid cystic carcinoma: a molecular profile update and potential implications. Front Oncol. 2023;13:1191218.","journal-title":"Front Oncol"},{"key":"3270_CR73","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.tranon.2014.07.006","volume":"7","author":"J Phuchareon","year":"2014","unstructured":"Phuchareon J, et al. c-Kit expression is rate-limiting for stem cell factor-mediated Disease Progression in Adenoid cystic carcinoma of the salivary glands. Transl Oncol. 2014;7:537\u201345.","journal-title":"Transl Oncol"},{"key":"3270_CR74","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/S0002-9440(10)64408-2","volume":"161","author":"HF Frierson Jr","year":"2002","unstructured":"Frierson HF Jr., et al. Large scale molecular analysis identifies genes with altered expression in salivary adenoid cystic carcinoma. Am J Pathol. 2002;161:1315\u201323.","journal-title":"Am J Pathol"},{"key":"3270_CR75","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.gendis.2022.11.023","volume":"11","author":"J Fan","year":"2024","unstructured":"Fan J, et al. Zinc finger protein 831 promotes apoptosis and enhances chemosensitivity in breast cancer by acting as a novel transcriptional repressor targeting the STAT3\/Bcl2 signaling pathway. Genes Dis. 2024;11:430\u201348.","journal-title":"Genes Dis"},{"key":"3270_CR76","doi-asserted-by":"crossref","unstructured":"Wang G, Sun D, Li W, Xin Y. AKNA Is a Potential Prognostic Biomarker in Gastric Cancer and Function as a Tumor Suppressor by Modulating EMT-Related Pathways. Biomed Res Int. 2020;2020:6726759.","DOI":"10.1155\/2020\/6726759"},{"key":"3270_CR77","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1038\/labinvest.3700314","volume":"85","author":"S Rutherford","year":"2005","unstructured":"Rutherford S, Hampton GM, Frierson HF, Moskaluk CA. Mapping of candidate tumor suppressor genes on chromosome 12 in adenoid cystic carcinoma. Lab Invest. 2005;85:1076\u201385.","journal-title":"Lab Invest"},{"key":"3270_CR78","first-page":"476","volume":"19","author":"XM Piao","year":"2020","unstructured":"Piao XM, et al. A novel tumor suppressing gene, ARHGAP9, is an independent prognostic biomarker for bladder cancer. Oncol Lett. 2020;19:476\u201386.","journal-title":"Oncol Lett"},{"key":"3270_CR79","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13148-020-00867-9","volume":"12","author":"J He","year":"2020","unstructured":"He J, et al. BTB\/POZ zinc finger protein ZBTB16 inhibits breast cancer proliferation and metastasis through upregulating ZBTB28 and antagonizing BCL6\/ZBTB27. Clin Epigenetics. 2020;12:82.","journal-title":"Clin Epigenetics"},{"key":"3270_CR80","doi-asserted-by":"crossref","unstructured":"Kim H et al. PRMT5 control of cGAS\/STING and NLRC5 pathways defines melanoma response to antitumor immunity. Sci Transl Med 12(2020).","DOI":"10.1126\/scitranslmed.aaz5683"},{"key":"3270_CR81","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1126\/science.aat5030","volume":"362","author":"DJ Theisen","year":"2018","unstructured":"Theisen DJ, et al. WDFY4 is required for cross-presentation in response to viral and tumor antigens. Science. 2018;362:694\u20139.","journal-title":"Science"},{"key":"3270_CR82","doi-asserted-by":"publisher","first-page":"1100231","DOI":"10.3389\/fimmu.2023.1100231","volume":"14","author":"Y Liu","year":"2023","unstructured":"Liu Y, et al. RASGRP2 is a potential immune-related biomarker and regulates mitochondrial-dependent apoptosis in lung adenocarcinoma. Front Immunol. 2023;14:1100231.","journal-title":"Front Immunol"},{"key":"3270_CR83","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.cels.2018.05.020","volume":"7","author":"JC Chen","year":"2018","unstructured":"Chen JC, Perez-Lorenzo R, Saenger YM, Drake CG, Christiano AM. IKZF1 enhances Immune infiltrate recruitment in solid tumors and susceptibility to Immunotherapy. Cell Syst. 2018;7:92\u2013e103104.","journal-title":"Cell Syst"},{"key":"3270_CR84","first-page":"4092","volume":"11","author":"S Sahara","year":"2021","unstructured":"Sahara S, Herzog AE, N\u00f6r JE. Systemic therapies for salivary gland adenoid cystic carcinoma. Am J Cancer Res. 2021;11:4092\u2013110.","journal-title":"Am J Cancer Res"},{"key":"3270_CR85","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1093\/bioinformatics\/btx441","volume":"33","author":"K Sidiropoulos","year":"2017","unstructured":"Sidiropoulos K, et al. Reactome enhanced pathway visualization. Bioinformatics. 2017;33:3461\u20137.","journal-title":"Bioinformatics"},{"key":"3270_CR86","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1172\/JCI69070","volume":"123","author":"HF Frierson Jr","year":"2013","unstructured":"Frierson HF Jr, Moskaluk CA. Mutation signature of adenoid cystic carcinoma: evidence for transcriptional and epigenetic reprogramming. J Clin Invest. 2013;123:2783\u20135.","journal-title":"J Clin Invest"},{"key":"3270_CR87","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1158\/1940-6207.CAPR-15-0316","volume":"9","author":"EM Rettig","year":"2016","unstructured":"Rettig EM, et al. Whole-genome sequencing of salivary gland adenoid cystic carcinoma. Cancer Prev Res (Phila). 2016;9:265\u201374.","journal-title":"Cancer Prev Res (Phila)"},{"key":"3270_CR88","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1172\/JCI67201","volume":"123","author":"PJ Stephens","year":"2013","unstructured":"Stephens PJ, et al. Whole exome sequencing of adenoid cystic carcinoma. J Clin Invest. 2013;123:2965\u20138.","journal-title":"J Clin Invest"},{"key":"3270_CR89","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/lary.20684","volume":"120","author":"A Oplatek","year":"2010","unstructured":"Oplatek A, Ozer E, Agrawal A, Bapna S, Schuller DE. Patterns of recurrence and survival of head and neck adenoid cystic carcinoma after definitive resection. Laryngoscope. 2010;120:65\u201370.","journal-title":"Laryngoscope"},{"key":"3270_CR90","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1002\/path.6172","volume":"261","author":"M Persson","year":"2023","unstructured":"Persson M, et al. Comprehensive molecular characterization of adenoid cystic carcinoma reveals tumor suppressors as novel drivers and prognostic biomarkers. J Pathol. 2023;261:256\u201368.","journal-title":"J Pathol"},{"key":"3270_CR91","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41392-022-00994-0","volume":"7","author":"Y You","year":"2022","unstructured":"You Y, et al. Artificial intelligence in cancer target identification and drug discovery. Signal Transduct Tar. 2022;7:156.","journal-title":"Signal Transduct Tar"},{"key":"3270_CR92","doi-asserted-by":"publisher","first-page":"10442","DOI":"10.1038\/s41598-019-46540-x","volume":"9","author":"Z Tong","year":"2019","unstructured":"Tong Z, Zhou Y, Wang J. Identifying potential drug targets in hepatocellular carcinoma based on network analysis and one-class support vector machine. Sci Rep. 2019;9:10442.","journal-title":"Sci Rep"},{"key":"3270_CR93","doi-asserted-by":"crossref","unstructured":"Gilvary C et al. A machine learning approach predicts essential genes and pharmacological targets in cancer. (bioRxiv, 2019).","DOI":"10.1101\/692277"},{"key":"3270_CR94","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/s41419-022-05437-w","volume":"13","author":"GV Mkrtchyan","year":"2022","unstructured":"Mkrtchyan GV, et al. High-confidence cancer patient stratification through multiomics investigation of DNA repair disorders. Cell Death Dis. 2022;13:999.","journal-title":"Cell Death Dis"},{"key":"3270_CR95","doi-asserted-by":"publisher","first-page":"D271","DOI":"10.1093\/nar\/gkh024","volume":"32","author":"R Zhang","year":"2004","unstructured":"Zhang R, Ou HY, Zhang CT. DEG: a database of essential genes. Nucleic Acids Res. 2004;32:D271\u2013272.","journal-title":"Nucleic Acids Res"},{"key":"3270_CR96","doi-asserted-by":"crossref","unstructured":"Carter J et al., Abstract 1138: PRMT5 inhibition downregulates MYB and NOTCH1 signaling, key molecular drivers of adenoid cystic carcinoma. Cancer Research. 2021;81:1138\u20131138.","DOI":"10.1158\/1538-7445.AM2021-1138"},{"key":"3270_CR97","doi-asserted-by":"publisher","first-page":"4437","DOI":"10.7150\/thno.42047","volume":"10","author":"M Liu","year":"2020","unstructured":"Liu M, et al. PRMT5-dependent transcriptional repression of c-Myc target genes promotes gastric cancer progression. Theranostics. 2020;10:4437\u201352.","journal-title":"Theranostics"},{"key":"3270_CR98","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1186\/s12885-019-6291-z","volume":"19","author":"NK Chaturvedi","year":"2019","unstructured":"Chaturvedi NK, et al. Role of protein arginine methyltransferase 5 in group 3 (MYC-driven) Medulloblastoma. BMC Cancer. 2019;19:1056.","journal-title":"BMC Cancer"},{"key":"3270_CR99","doi-asserted-by":"publisher","first-page":"e57008","DOI":"10.1371\/journal.pone.0057008","volume":"8","author":"MC Ho","year":"2013","unstructured":"Ho MC, et al. Structure of the arginine methyltransferase PRMT5-MEP50 reveals a mechanism for substrate specificity. PLoS ONE. 2013;8:e57008.","journal-title":"PLoS ONE"},{"key":"3270_CR100","doi-asserted-by":"publisher","first-page":"9674","DOI":"10.1074\/jbc.M115.636894","volume":"290","author":"ES Burgos","year":"2015","unstructured":"Burgos ES, et al. Histone H2A and H4 N-terminal tails are positioned by the MEP50 WD repeat protein for efficient methylation by the PRMT5 arginine methyltransferase. J Biol Chem. 2015;290:9674\u201389.","journal-title":"J Biol Chem"},{"key":"3270_CR101","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.oraloncology.2018.10.012","volume":"87","author":"KA Warner","year":"2018","unstructured":"Warner KA, et al. UM-HACC-2A: MYB-NFIB fusion-positive human adenoid cystic carcinoma cell line. Oral Oncol. 2018;87:21\u20138.","journal-title":"Oral Oncol"},{"key":"3270_CR102","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.oraloncology.2019.09.005","volume":"98","author":"Y Jiang","year":"2019","unstructured":"Jiang Y, et al. MYB-activated models for testing therapeutic agents in adenoid cystic carcinoma. Oral Oncol. 2019;98:147\u201355.","journal-title":"Oral Oncol"},{"key":"3270_CR103","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.3390\/cancers14092263","volume":"14","author":"JO Humtsoe","year":"2022","unstructured":"Humtsoe JO, et al. Development and characterization of MYB-NFIB Fusion expression in Adenoid cystic carcinoma. Cancers. 2022;14:2263.","journal-title":"Cancers"},{"key":"3270_CR104","doi-asserted-by":"crossref","unstructured":"Zhang Y et al., Abstract 2919: Discovery of PRT811, a potent, selective, and orally bioavailable brain penetrant PRMT5 Inhibitor for the treatment of brain tumors. Cancer Research. 2020;80:2919\u20132919.","DOI":"10.1158\/1538-7445.AM2020-2919"},{"key":"3270_CR105","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1002\/hed.23925","volume":"38","author":"PM Dillon","year":"2016","unstructured":"Dillon PM, Chakraborty S, Moskaluk CA, Joshi PJ, Thomas CY. Adenoid cystic carcinoma: a review of recent advances, molecular targets, and clinical trials. Head Neck. 2016;38:620\u20137.","journal-title":"Head Neck"},{"key":"3270_CR106","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41392-022-00994-0","volume":"7","author":"Y You","year":"2022","unstructured":"You Y, et al. Artificial intelligence in cancer target identification and drug discovery. Signal Transduct Target Ther. 2022;7:156.","journal-title":"Signal Transduct Target Ther"},{"key":"3270_CR107","doi-asserted-by":"publisher","first-page":"110255","DOI":"10.1016\/j.biopha.2020.110255","volume":"128","author":"G Liang","year":"2020","unstructured":"Liang G, Fan W, Luo H, Zhu X. The emerging roles of artificial intelligence in cancer drug development and precision therapy. Biomed Pharmacother. 2020;128:110255.","journal-title":"Biomed Pharmacother"},{"key":"3270_CR108","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1093\/bib\/bbz122","volume":"21","author":"J Paananen","year":"2020","unstructured":"Paananen J, Fortino V. An omics perspective on drug target discovery platforms. Brief Bioinform. 2020;21:1937\u201353.","journal-title":"Brief Bioinform"},{"key":"3270_CR109","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1021\/acs.molpharmaceut.6b00248","volume":"13","author":"A Aliper","year":"2016","unstructured":"Aliper A, et al. Deep Learning Applications for Predicting Pharmacological properties of drugs and Drug Repurposing using Transcriptomic Data. Mol Pharm. 2016;13:2524\u201330.","journal-title":"Mol Pharm"},{"key":"3270_CR110","doi-asserted-by":"publisher","first-page":"e14017","DOI":"10.1111\/acel.14017","volume":"22","author":"FW Pun","year":"2023","unstructured":"Pun FW, et al. A comprehensive AI-driven analysis of large-scale omic datasets reveals novel dual-purpose targets for the treatment of cancer and aging. Aging Cell. 2023;22:e14017.","journal-title":"Aging Cell"},{"key":"3270_CR111","doi-asserted-by":"crossref","unstructured":"Kumar D, Jain S, Coulter DW, Joshi SS. & Chaturvedi, N.K. PRMT5 as a potential therapeutic target in MYC-Amplified Medulloblastoma. Cancers (Basel) 15(2023).","DOI":"10.3390\/cancers15245855"},{"key":"3270_CR112","doi-asserted-by":"crossref","unstructured":"Orben F et al. Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype. JCI Insight 7(2022).","DOI":"10.1172\/jci.insight.151353"},{"key":"3270_CR113","doi-asserted-by":"publisher","first-page":"101788","DOI":"10.1016\/j.tice.2022.101788","volume":"76","author":"L Zhang","year":"2022","unstructured":"Zhang L, Shao G, Shao J, Zhao J. PRMT5-activated c-Myc promote bladder cancer proliferation and invasion through up-regulating NF-\u03baB pathway. Tissue Cell. 2022;76:101788.","journal-title":"Tissue Cell"},{"key":"3270_CR114","doi-asserted-by":"crossref","unstructured":"McKean M et al. A phase 1 dose escalation study of protein arginine methyltransferase 5 (PRMT5) inhibitor PRT543 in patients with advanced solid tumors and lymphoma. Mol Cancer Ther 20(2021).","DOI":"10.1158\/1535-7163.TARG-21-P039"},{"key":"3270_CR115","doi-asserted-by":"crossref","unstructured":"Patel MR et al. A phase 1 dose escalation study of protein arginine methyltransferase 5 (PRMT5) inhibitor PRT543 in patients with myeloid malignancies. Blood 138(2021).","DOI":"10.1182\/blood-2021-150938"},{"key":"3270_CR116","doi-asserted-by":"publisher","first-page":"3592","DOI":"10.1158\/1078-0432.CCR-23-0092","volume":"29","author":"M Vieito","year":"2023","unstructured":"Vieito M, et al. Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in Advanced Solid tumors. Clin Cancer Res. 2023;29:3592\u2013602.","journal-title":"Clin Cancer Res"},{"key":"3270_CR117","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1158\/1535-7163.MCT-21-0367","volume":"20","author":"D Brehmer","year":"2021","unstructured":"Brehmer D, et al. Discovery and Pharmacological characterization of JNJ-64619178, a Novel small-molecule inhibitor of PRMT5 with Potent Antitumor Activity. Mol Cancer Ther. 2021;20:2317\u201328.","journal-title":"Mol Cancer Ther"},{"key":"3270_CR118","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1182\/blood-2021-146987","volume":"138","author":"T Haque","year":"2021","unstructured":"Haque T, et al. Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with Lower-Risk Myelodysplastic syndromes. Blood. 2021;138:2606\u20132606.","journal-title":"Blood"},{"key":"3270_CR119","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1158\/2159-8290.CD-23-0669","volume":"13","author":"LD Engstrom","year":"2023","unstructured":"Engstrom LD, et al. MRTX1719 is an MTA-Cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP-Deleted Cancer. Cancer Discov. 2023;13:2412\u201331.","journal-title":"Cancer Discov"},{"key":"3270_CR120","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1158\/2159-8290.CD-NB2023-0079","volume":"13","author":"AMG 193","year":"2023","unstructured":"AMG 193. Effective in multiple tumor types. Cancer Discov. 2023;13:2492\u20132492.","journal-title":"Cancer Discov"},{"key":"3270_CR121","doi-asserted-by":"crossref","unstructured":"Zhang M et al., Abstract 3452: TNG908, a brain-penetrant MTA-cooperative PRMT5 inhibitor, is efficacious in preclinical glioblastoma models. Cancer Research. 2023;83:3452\u20133452.","DOI":"10.1158\/1538-7445.AM2023-3452"},{"key":"3270_CR122","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1016\/S0046-8177(99)90044-8","volume":"30","author":"LA Cerilli","year":"1999","unstructured":"Cerilli LA, et al. Analysis of chromosome 9p21 deletion and p16 gene mutation in salivary gland carcinomas. Hum Pathol. 1999;30:1242\u20136.","journal-title":"Hum Pathol"},{"key":"3270_CR123","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1093\/annonc\/mdw287","volume":"27","author":"AL Ho","year":"2016","unstructured":"Ho AL, et al. A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma. Ann Oncol. 2016;27:1902\u20138.","journal-title":"Ann Oncol"},{"key":"3270_CR124","doi-asserted-by":"publisher","first-page":"4555","DOI":"10.1158\/1078-0432.CCR-23-1030","volume":"29","author":"GJ Hanna","year":"2023","unstructured":"Hanna GJ, et al. A phase II trial of Rivoceranib, an oral vascular endothelial growth factor receptor 2 inhibitor, for recurrent or metastatic adenoid cystic carcinoma. Clin Cancer Res. 2023;29:4555\u201363.","journal-title":"Clin Cancer Res"},{"key":"3270_CR125","doi-asserted-by":"publisher","first-page":"7334","DOI":"10.1158\/1078-0432.CCR-05-0241","volume":"11","author":"J Zhang","year":"2005","unstructured":"Zhang J, Peng B, Chen X. Expressions of nuclear factor kappaB, inducible nitric oxide synthase, and vascular endothelial growth factor in adenoid cystic carcinoma of salivary glands: correlations with the angiogenesis and clinical outcome. Clin Cancer Res. 2005;11:7334\u201343.","journal-title":"Clin Cancer Res"},{"key":"3270_CR126","doi-asserted-by":"publisher","first-page":"518","DOI":"10.4143\/crt.2015.093","volume":"48","author":"S Park","year":"2016","unstructured":"Park S, et al. VEGF and Ki-67 overexpression in Predicting Poor overall survival in Adenoid cystic carcinoma. Cancer Res Treat. 2016;48:518\u201326.","journal-title":"Cancer Res Treat"},{"key":"3270_CR127","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.ejca.2016.09.022","volume":"69","author":"LD Locati","year":"2016","unstructured":"Locati LD, et al. A phase II study of sorafenib in recurrent and\/or metastatic salivary gland carcinomas: translational analyses and clinical impact. Eur J Cancer. 2016;69:158\u201365.","journal-title":"Eur J Cancer"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-024-03270-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-024-03270-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-024-03270-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T23:29:26Z","timestamp":1736551766000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-024-03270-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,11]]},"references-count":127,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3270"],"URL":"https:\/\/doi.org\/10.1186\/s13046-024-03270-x","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,11]]},"assertion":[{"value":"22 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All human samples used in this study were obtained by the Human Tissue Resource Center at the University of Chicago following informed written consent, under the Institutional Review Boards (IRB)-approved protocols.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"VT, KI, PS, and BR are affiliated with Prelude Therapeutics, a clinical-stage biopharmaceutical company designing and developing novel small molecule therapies that target the key drivers of cancer cell growth and resistance. MK, VS, AO, OG, IO, FP, and AZ are affiliated with InSilico Medicine, a company developing an AI-based end-to-end integrated pipeline for drug discovery and development. The remaining authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11"}}